ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Markets/EquitiesArticle

Amagi Q1 FY27 profit rises as AI pilots scale up

Ad-tech firm Amagi reports first-quarter profit growth for FY27, driven by expanding AI-based pilot projects. Revenue and margin details remain undisclosed.

PA
Priya Anand · Equities & Earnings Desk · 16 Aug 2026 · 1 min read
Share
Amagi Q1 FY27 profit rises as AI pilots scale up

Amagi, a provider of cloud-based ad-tech solutions, said first-quarter profit for the fiscal year ending March 2027 rose as AI-driven pilot projects scaled up.

The company disclosed the improvement in profitability in a presentation slide deck published on Thursday, though it did not provide specific revenue or margin figures. The expansion of AI pilots was cited as the primary driver behind the earnings growth.

Amagi has been increasingly integrating artificial intelligence into its advertising technology stack to enhance targeting, automation, and efficiency for broadcasters and digital platforms. The pilots, which remain in early commercial stages, are expected to contribute materially to future revenue streams as adoption accelerates.

Executives did not comment on the financial impact of the AI initiatives beyond the profitability increase. The company’s broader business strategy continues to focus on cloud-based ad delivery and monetization solutions, with AI serving as a key differentiator in a competitive market.

Amagi’s latest update follows a period of heightened investor scrutiny over ad-tech firms amid shifting digital advertising trends and rising demand for AI-enabled tools. The company’s shares are not publicly traded, limiting direct market reaction to the disclosure.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT